Forte Biosciences (FBRX) Expected to Release Earnings on Thursday

Forte Biosciences (NASDAQ:FBRX) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.8785) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Forte Biosciences (NASDAQ:FBRX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.08). On average, analysts expect Forte Biosciences to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Forte Biosciences Stock Up 0.1%

NASDAQ FBRX opened at $76.61 on Thursday. The stock has a market capitalization of $1.06 billion, a PE ratio of -16.51 and a beta of 2.62. Forte Biosciences has a 12-month low of $9.10 and a 12-month high of $77.20. The company has a 50 day moving average price of $35.05 and a two-hundred day moving average price of $30.60.

Analysts Set New Price Targets

FBRX has been the topic of a number of recent research reports. Brookline Capital Markets downgraded shares of Forte Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, July 27th. TD Cowen cut shares of Forte Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, July 27th. Evercore set a $77.00 price target on Forte Biosciences in a research report on Monday, July 27th. Weiss Ratings downgraded Forte Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Finally, Wall Street Zen lowered Forte Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $72.50.

Institutional Trading of Forte Biosciences

Several large investors have recently modified their holdings of the company. Geode Capital Management LLC grew its stake in Forte Biosciences by 6.7% in the 2nd quarter. Geode Capital Management LLC now owns 64,110 shares of the company’s stock valued at $829,000 after buying an additional 4,028 shares during the last quarter. Orbimed Advisors LLC lifted its position in Forte Biosciences by 101.8% during the 2nd quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company’s stock worth $15,477,000 after acquiring an additional 603,867 shares during the last quarter. Cable Car Capital LP lifted its position in Forte Biosciences by 127.7% during the 2nd quarter. Cable Car Capital LP now owns 500,000 shares of the company’s stock worth $6,465,000 after acquiring an additional 280,396 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Forte Biosciences during the second quarter valued at about $4,310,000. Finally, Mink Brook Asset Management LLC bought a new stake in Forte Biosciences during the second quarter valued at about $503,000. 77.63% of the stock is owned by institutional investors.

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.